cAd3-EBO (GSK)

cAd3-EBO is an investigational monovalent viral vector vaccine developed by the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with GSK (following the acquisition of Okairos). The vaccine utilizes a replication-deficient chimpanzee adenovirus type 3 (cAd3) vector to deliver the gene encoding the glycoprotein (GP) of the Zaire ebolavirus (Mayinga strain). Upon intramuscular administration, the vector enters host cells and expresses the EBOV GP, which serves as an antigen to stimulate the production of virus-specific neutralizing antibodies and activate CD8+ T-cell responses. It was primarily evaluated during the 2014-2016 West Africa Ebola outbreak in Phase 1 and Phase 2 clinical trials (such as VRC 207 and PREVAIL I) to assess safety and immunogenicity. In 2019, GSK transferred the development rights for the cAd3 Ebola vaccine platform to the Sabin Vaccine Institute.

Other names

Monovalent cAd3-ZEBOV vaccineChimpanzee Adenovirus Type 3 Ebola VaccinecAd3-Ebola Zaire vaccinecAd-3-Ebola Zaire vaccinecAd 3-Ebola Zaire vaccine